[go: up one dir, main page]

MA32894B1 - Combinaisons anticancéreuses contenant des anticorps reconnaissant spécifiquement cd38 et du cyclophosphamide - Google Patents

Combinaisons anticancéreuses contenant des anticorps reconnaissant spécifiquement cd38 et du cyclophosphamide

Info

Publication number
MA32894B1
MA32894B1 MA33935A MA33935A MA32894B1 MA 32894 B1 MA32894 B1 MA 32894B1 MA 33935 A MA33935 A MA 33935A MA 33935 A MA33935 A MA 33935A MA 32894 B1 MA32894 B1 MA 32894B1
Authority
MA
Morocco
Prior art keywords
cyclophosphamide
antibodies
specifically recognizing
combinations containing
containing specifically
Prior art date
Application number
MA33935A
Other languages
Arabic (ar)
English (en)
Inventor
Pascale Lejeune
Patricia Vrignaud
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MA32894B1 publication Critical patent/MA32894B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/664—Amides of phosphorus acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention concerne une composition pharmaceutique comprenant un anticorps reconnaissant spécifiquement CD38 et du cyclophosphamide.
MA33935A 2008-11-28 2011-06-13 Combinaisons anticancéreuses contenant des anticorps reconnaissant spécifiquement cd38 et du cyclophosphamide MA32894B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08291119A EP2191843A1 (fr) 2008-11-28 2008-11-28 Combinaisons antitumorales contenant des anticorps reconnaissant spécifiquement les CD38 et cyclophosphamide
PCT/IB2009/055392 WO2010061360A1 (fr) 2008-11-28 2009-11-27 Associations antitumorales contenant des anticorps reconnaissant spécifiquement cd38 et du cyclophosphamide

Publications (1)

Publication Number Publication Date
MA32894B1 true MA32894B1 (fr) 2011-12-01

Family

ID=40637068

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33935A MA32894B1 (fr) 2008-11-28 2011-06-13 Combinaisons anticancéreuses contenant des anticorps reconnaissant spécifiquement cd38 et du cyclophosphamide

Country Status (29)

Country Link
US (2) US20110305690A1 (fr)
EP (2) EP2191843A1 (fr)
JP (3) JP2012510464A (fr)
KR (1) KR101749770B1 (fr)
CN (1) CN102264387B (fr)
AR (1) AR074221A1 (fr)
AU (1) AU2009321252B2 (fr)
BR (1) BRPI0922305B1 (fr)
CA (1) CA2745012C (fr)
CL (1) CL2011001256A1 (fr)
CO (1) CO6361947A2 (fr)
CR (1) CR20110283A (fr)
EA (2) EA032934B1 (fr)
EC (1) ECSP11011077A (fr)
HN (1) HN2011001426A (fr)
MA (1) MA32894B1 (fr)
ME (1) ME01139B (fr)
MX (1) MX340062B (fr)
MY (1) MY166530A (fr)
NI (1) NI201100104A (fr)
NZ (1) NZ593147A (fr)
PA (1) PA8850201A1 (fr)
PE (1) PE20110822A1 (fr)
SV (1) SV2011003925A (fr)
TW (1) TWI457346B (fr)
UA (1) UA104161C2 (fr)
UY (1) UY32267A (fr)
WO (1) WO2010061360A1 (fr)
ZA (1) ZA201103920B (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2191840A1 (fr) 2008-11-28 2010-06-02 Sanofi-Aventis Combinaisons antitumorales contenant des anticorps reconnaissant spécifiquement les CD38 et melphalan
BR112013006769B1 (pt) 2010-09-27 2021-02-02 Morphosys Ag combinação sinérgica
UA112170C2 (uk) * 2010-12-10 2016-08-10 Санофі Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
PL2900232T3 (pl) 2012-09-25 2018-05-30 Morphosys Ag Kombinacje i ich zastosowania
UA118255C2 (uk) * 2012-12-07 2018-12-26 Санофі Композиція, яка містить антитіло до cd38 і леналідомід
US10342869B2 (en) 2012-12-07 2019-07-09 The Regents Of The University Of California Compositions comprising anti-CD38 antibodies and lenalidomide
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
MA39070A1 (fr) 2014-07-31 2017-11-30 Sanofi Sa Anticorps anti-cd38 spécifiques pour le traitement de cancers humains
US10617757B2 (en) 2014-08-08 2020-04-14 The Regents Of The University Of California Methods for treating multiple myeloma
EA035979B1 (ru) 2014-09-09 2020-09-08 Янссен Байотек, Инк. Варианты комбинированной терапии анти-cd38 антителами
KR102597989B1 (ko) 2014-12-04 2023-11-02 얀센 바이오테크 인코포레이티드 급성 골수성 백혈병을 치료하기 위한 항-cd38 항체
IL319936A (en) 2015-05-20 2025-05-01 Janssen Biotech Inc Anti-CD38 antibodies for the treatment of light chain amyloidosis and other CD38-positive hematological malignancies
WO2016209921A1 (fr) 2015-06-22 2016-12-29 Janssen Biotech, Inc. Polythérapies pour malignités hématologiques avec des anticorps anti-cd38 et des inhibiteurs de la survivine
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
EP4516319A3 (fr) 2015-11-03 2025-05-07 Janssen Biotech, Inc. Formulations sous-cutanées d'anticorps anti-cd38 et leurs utilisations
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
CN109689690B (zh) 2016-07-15 2023-10-03 武田药品工业株式会社 用于评估对于成浆细胞和浆细胞耗竭性疗法的应答的方法和材料
WO2019035938A1 (fr) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. Molécules multispécifiques se liant à bcma et leurs utilisations
MA50514A (fr) 2017-10-31 2020-09-09 Janssen Biotech Inc Méthodes de traitement du myélome multiple à haut risque
CA3088199A1 (fr) 2018-01-12 2019-07-18 Takeda Pharmaceutical Company Limited Dosage sous-cutane d'anticorps anti-cd38
CN113574071B (zh) 2019-03-15 2025-03-25 莫佛塞斯公司 用于治疗自身抗体介导的自身免疫疾病的抗-cd38抗体及其药物组合物
US11655302B2 (en) 2019-06-10 2023-05-23 Sanofi Anti-CD38 antibodies and formulations
IL293563A (en) 2019-12-05 2022-08-01 Sanofi Aventis Us Llc Formulations of anti-cd38 antibodies for subcutaneous administration
TW202235435A (zh) 2021-01-14 2022-09-16 德商莫菲西斯公司 抗cd38抗體及其用途
TW202302642A (zh) 2021-03-01 2023-01-16 德商莫菲西斯公司 用於治療抗體介導移植物排斥用途之抗ｃｄ３８抗體
TW202321303A (zh) 2021-07-19 2023-06-01 德商莫菲西斯公司 抗pla2r自體抗體媒介膜性腎病變之治療

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
ATE139258T1 (de) 1990-01-12 1996-06-15 Cell Genesys Inc Erzeugung xenogener antikörper
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
EP0940468A1 (fr) 1991-06-14 1999-09-08 Genentech, Inc. Domaine variable d'un anticorps humanisé
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
EP0822830B1 (fr) 1995-04-27 2008-04-02 Amgen Fremont Inc. Anticorps anti-IL-8 dérivés de xenosouris immunisées
EP0823941A4 (fr) 1995-04-28 2001-09-19 Abgenix Inc Anticorps humains derives de xeno-souris immunisees
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
EP1500329B1 (fr) 1996-12-03 2012-03-21 Amgen Fremont Inc. Les anticorps humains qui lient en particulier l'alpha de TNF humain
DE69800716T2 (de) 1997-04-14 2001-09-20 Micromet Gesellschaft Fuer Biomedizinische Forschung Mbh Neues verfahren zur herstellung von anti-humanen antigenrezeptoren und deren verwendungen
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
CA2329940A1 (fr) * 1998-06-05 1999-12-09 Mayo Foundation For Medical Education And Research Traitement du myelome multiple au moyen d'anticorps du cd38 obtenus par genie genetique
GB0221574D0 (en) * 2002-09-17 2002-10-23 Isis Innovation Treatments
SG10201912554TA (en) * 2005-03-23 2020-02-27 Genmab As Antibodies against cd38 for treatment of multiple myeloma
EP1914242A1 (fr) * 2006-10-19 2008-04-23 Sanofi-Aventis Nouveau anticorps Anti-CD38 pour le traitement du cancer
EP2245065A1 (fr) * 2008-01-23 2010-11-03 Xencor, Inc. Anticorps dirigés contre cd40 optimisés et leurs procédés d'utilisation
UA112170C2 (uk) * 2010-12-10 2016-08-10 Санофі Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб

Also Published As

Publication number Publication date
UA104161C2 (uk) 2014-01-10
KR20110096552A (ko) 2011-08-30
CR20110283A (es) 2011-09-20
TW201024315A (en) 2010-07-01
ZA201103920B (en) 2012-09-26
CN102264387A (zh) 2011-11-30
KR101749770B1 (ko) 2017-06-22
PE20110822A1 (es) 2011-11-22
AR074221A1 (es) 2010-12-29
EA201100869A1 (ru) 2011-10-31
CA2745012C (fr) 2020-09-15
EP2191843A1 (fr) 2010-06-02
NI201100104A (es) 2011-09-26
JP6018235B2 (ja) 2016-11-02
JP2017036297A (ja) 2017-02-16
BRPI0922305A2 (pt) 2016-06-21
EP2370097B1 (fr) 2019-01-09
BRPI0922305B1 (pt) 2022-04-05
MX340062B (es) 2016-06-23
ME01139B (me) 2013-03-20
ECSP11011077A (es) 2011-07-29
MX2011005538A (es) 2011-10-10
CO6361947A2 (es) 2012-01-20
CA2745012A1 (fr) 2010-06-03
UY32267A (es) 2010-06-30
NZ593147A (en) 2012-12-21
WO2010061360A1 (fr) 2010-06-03
EP2370097A1 (fr) 2011-10-05
SV2011003925A (es) 2011-10-07
AU2009321252A1 (en) 2010-06-03
JP6215429B2 (ja) 2017-10-18
EA026008B1 (ru) 2017-02-28
JP2012510464A (ja) 2012-05-10
HN2011001426A (es) 2014-01-13
JP2015120729A (ja) 2015-07-02
AU2009321252B2 (en) 2016-06-09
PA8850201A1 (es) 2010-07-27
HK1164154A1 (en) 2012-09-21
EA201692041A1 (ru) 2017-05-31
MY166530A (en) 2018-07-10
EA032934B1 (ru) 2019-08-30
CL2011001256A1 (es) 2012-01-27
TWI457346B (zh) 2014-10-21
US20170056496A1 (en) 2017-03-02
CN102264387B (zh) 2015-04-08
US20110305690A1 (en) 2011-12-15

Similar Documents

Publication Publication Date Title
MA32894B1 (fr) Combinaisons anticancéreuses contenant des anticorps reconnaissant spécifiquement cd38 et du cyclophosphamide
MA32895B1 (fr) Combinaisons anticancéreuses contenant des anticorps reconnaissant spécifiquement cd38 et de la vincristine
MA32896B1 (fr) Combinaisons anticancereuses contenant des anticorps reconnaissant specifiquement cd38 et du melphalan
MA32899B1 (fr) Combinaisons anticancereuses contenant des anticorps reconnaissant specifiquement cd38 et de la cytarabine
MA34816B1 (fr) Combinaisons antitumorales contenant des anticorps reconnaissant specifiquement le cd38 et du bortezomib
MA33537B1 (fr) Anticorps anti-cdcp1 humanisés
EP2484697A4 (fr) Anticorps antipodoplanine et composition pharmaceutique contenant un anticorps antipodoplanine
TR201109686T2 (tr) Olmesartan'ın Farmasötik Bileşimleri.
FR2963561B1 (fr) Composition pharmaceutique contenant un extrait de serenoa repens
MA55298A (fr) Compositions pharmaceutiques contenant des anticorps anti-lingo-1
TN2011000153A1 (en) Antitumor combinations containing antibodies recognizing specifically cd38 and cylophosphamide